These distributions are consistent with the observed distributions of other EGFR oncogenic mutations in glioblastoma13,15 and NSCLC14,16 and other ERBB2 mutations in breast cancer19, supporting the notion that specific genes may be genomically altered through a variety of mechanisms in a given tumor context. Here, EGFR is linked to neoplasm.